Ask AI
CDK4 6i in HR Pos HER2 Neg Breast Cancer

CE

Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: April 15, 2026

Expiration: October 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 58-year-old postmenopausal woman with T2N1, high-grade hormone receptor (HR)–positive/HER2-negative early breast cancer started adjuvant abemaciclib 2 months ago. She reports ≥7 loose stools/day (grade 3 diarrhea) despite as-needed (PRN) loperamide, with stable weight and oral intake, and new fatigue affecting work. You instruct her to hold abemaciclib and start a structured antidiarrheal plan. What additional counseling is the most appropriate next step in her treatment?

2.

A 72-year-old patient with HR-positive/HER2-negative metastatic breast cancer is receiving abemaciclib plus fulvestrant. At her 1-month follow-up visit, she expresses feeling overwhelmed by the pill burden and is significantly stressed by the high out-of-pocket costs. She is now considering stopping treatment. How would you counsel this patient?